The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksGlaxosmithkline Share News (GSK)

Share Price Information for Glaxosmithkline (GSK)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1,733.50
Bid: 1,732.50
Ask: 1,733.00
Change: 0.00 (0.00%)
Spread: 0.50 (0.029%)
Open: 0.00
High: 0.00
Low: 0.00
Prev. Close: 1,733.50
GSK Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

UPDATE 3-Zika virus set to spread across Americas, spurring vaccine hunt

Mon, 25th Jan 2016 17:14

* Mosquito-borne virus linked to birth defects in Brazil

* Brazil's Butantan Institute aims to develop vaccine

* GSK and Sanofi reviewing vaccine possibilities

* More research needed into potential sexual transmission (Adds comment from GlaxoSmithKline and Sanofi, graphic link)

By Tom Miles and Ben Hirschler

GENEVA/LONDON, Jan 25 (Reuters) - The mosquito-borne Zikavirus, which has been linked to brain damage in thousands ofbabies in Brazil, is likely to spread to all countries in theAmericas except for Canada and Chile, the World HealthOrganization said on Monday.

Zika transmission has not yet been reported in thecontinental United States, although a woman who fell ill withthe virus in Brazil later gave birth to a brain-damaged baby inHawaii.

Brazil's Health Ministry said in November that Zika waslinked to a foetal deformation known as microcephaly, in whichinfants are born with smaller-than-usual brains.

Brazil has reported 3,893 suspected cases of microcephaly,the WHO said last Friday, over 30 times more than in any yearsince 2010 and equivalent to 1-2 percent of all newborns in thestate of Pernambuco, one of the worst-hit areas.

The Zika outbreak comes hard on the heels of the Ebolaepidemic in West Africa, demonstrating once again howlittle-understood diseases can rapidly emerge as global threats.

"We've got no drugs and we've got no vaccines. It's a caseof deja vu because that's exactly what we were saying withEbola," said Trudie Lang, a professor of global health at theUniversity of Oxford. "It's really important to develop avaccine as quickly as possible."

Large drugmakers' investment in tropical disease vaccineswith uncertain commercial prospects has so far been patchy,prompting health experts to call for a new system of incentivesfollowing the Ebola experience.

"We need to have some kind of a plan that makes (companies)feel there is a sustainable solution and not just a one-shotdeal over and over again," Francis Collins, director of the U.S.National Institutes of Health, said last week.

The Sao Paulo-based Butantan Institute is currently leadingthe research charge on Zika and said last week it planned todevelop a vaccine "in record time", although its director warnedthis was still likely to take three to five years.

British drugmaker GlaxoSmithKline said on Monday itwas studying the feasibility of using its vaccine technology onZika, while France's Sanofi said it was reviewingpossibilities.

RIO CONCERNS

The virus was first found in a monkey in the Zika forestnear Lake Victoria, Uganda, in 1947, and has historicallyoccurred in parts of Africa, Southeast Asia and the PacificIslands. But there is little scientific data on it and it isunclear why it might be causing microcephaly in Brazil.

Laura Rodrigues of the London School of Hygiene and TropicalMedicine said it was possible the disease could be evolving.

If the epidemic was still going on in August, when Brazil isdue to host the Olympic Games in Rio de Janeiro, then pregnantwomen should either stay away or be obsessive about covering upagainst mosquito bites, she said.

The WHO advised pregnant women planning to travel to areaswhere Zika is circulating to consult a healthcare providerbefore travelling and on return.

The clinical symptoms of Zika are usually mild and oftensimilar to dengue, a fever which is transmitted by the sameAedes aegypti mosquito, leading to fears that Zika will spreadinto all parts of the world where dengue is commonplace.

More than one-third of the world's population lives in areasat risk of dengue infection, in a band stretching throughAfrica, India, Southeast Asia and Latin America.

Zika's rapid spread, to 21 countries and territories in theAmericas since May 2015, is due to the prevalence of Aedesaegypti and a lack of immunity among the population, the WHOsaid in a statement.

RISK TO GIRLS

Like rubella, which also causes mild symptoms but can leadto birth defects, health experts believe a vaccine is needed toprotect girls before they reach child-bearing age.

Evidence about other transmission routes, apart frommosquito bites, is limited.

"Zika has been isolated in human semen, and one case ofpossible person-to-person sexual transmission has beendescribed. However, more evidence is needed to confirm whethersexual contact is a means of Zika transmission," the WHO said.

While a causal link between Zika and microcephaly has notyet been definitively proven, WHO Director-General Margaret Chansaid the circumstantial evidence was "suggestive and extremelyworrisome".

In addition to finding a vaccine and potential drugs tofight Zika, some scientists are also planning to take the fightto the mosquitoes that carry the disease.

Oxitec, the UK subsidiary of U.S. synthetic biology companyIntrexon, hopes to deploy a self-limiting geneticallymodified strain of insects to compete with normal Aedes aegypti.

Oxitec says its proprietary OX513A mosquito succeeded inreducing wild larvae of the Aedes mosquito by 82 percent in anarea of Brazil where 25 million of the transgenic insects werereleased between April and November. Authorities reported a bigdrop in dengue cases in the area.

(Editing by Mark Trevelyan)

More News
22 Nov 2023 09:48

LONDON BROKER RATINGS: RBC cuts HSBC; Liberum cuts Glencore

(Alliance News) - The following London-listed shares received analyst recommendations Wednesday morning and Tuesday:

Read more
21 Nov 2023 11:52

GSK to begin phase 3 trials of low-carbon Ventolin inhaler in 2024

(Alliance News) - GSK PLC on Tuesday said it will begin phase 3 trials of a low carbon version of its metered dose inhaler Ventolin using a "next generation" propellant in 2024.

Read more
14 Nov 2023 17:04

LONDON MARKET CLOSE: FTSE 100 underwhelms as stocks jump after US CPI

(Alliance News) - European equities jumped in the wake of a cooler-than-expected US inflation reading, which took some sting out of a recent hawkish reassessment of the Federal Reserve interest rate outlook.

Read more
13 Nov 2023 09:47

GSK hails momelotinib opinion from European Medicines Agency committee

(Alliance News) - GSK PLC on Monday announced that a European Medicines Agency panel has given a positive opinion recommending momelotinib to treat myelofibrosis patients with anaemia.

Read more
9 Nov 2023 15:50

UK dividends calendar - next 7 days

Friday 10 November 
Bodycote PLCdividend payment date
Breedon Group PLCdividend payment date
Chesnara PLCdividend payment date
Finsbury Growth & Income Trust PLCdividend payment date
Invesco Bond Income Plus Ltddividend payment date
JPMorgan Emerging Markets Investment Trust PLCdividend payment date
Kerry Group PLCdividend payment date
Merchants Trust PLCdividend payment date
Mid Wynd International Investment Trust PLCdividend payment date
Mid Wynd International Investment Trust PLCspecial dividend payment date
Montanaro UK Smaller Cos Investment Trust PLCdividend payment date
Senior PLCdividend payment date
Spectris PLCdividend payment date
Spirax-Sarco Engineering PLCdividend payment date
Travis Perkins PLCdividend payment date
Monday 13 November 
no events scheduled 
Tuesday 14 November 
no events scheduled 
Wednesday 15 November 
Coats Group PLCdividend payment date
Ferguson PLCdividend payment date
JP Morgan Mid Cap Investment Trust PLCdividend payment date
Strategic Equity Capital PLCdividend payment date
Thursday 16 November 
abrdn Property Income Trust Ltdex-dividend payment date
Asian Energy Impact Trust PLCex-dividend payment date
Baillie Gifford Japan Trust PLCex-dividend payment date
BlackRock Greater Europe Investment Trust PLCex-dividend payment date
Bunzl PLCex-dividend payment date
Bytes Technology Group PLCex-dividend payment date
Centrica PLCdividend payment date
Coca-Cola Europacific Partners PLCex-dividend payment date
DX Group PLCex-dividend payment date
Empiric Student Property PLCex-dividend payment date
Fonix Mobile PLCex-dividend payment date
GCP Asset Backed Income Fund Ltdex-dividend payment date
GSK PLCex-dividend payment date
Hargreaves Lansdown PLCex-dividend payment date
Henderson Opportunities Trust PLCex-dividend payment date
ICG Enterprise Trust PLCex-dividend payment date
James Halstead PLCex-dividend payment date
Lancashire Holdings Ltdspecial ex-dividend payment date
Majedie Investments PLCex-dividend payment date
Marks & Spencer Group PLCex-dividend payment date
Murray Income Trust PLCex-dividend payment date
New Star Investment Trust PLCex-dividend payment date
NextEnergy Solar Fund Ltdex-dividend payment date
Octopus Renewables Infrastructure Trust PLCex-dividend payment date
Pershing Square Holdings Ltdex-dividend payment date
Personal Group Holdings PLCdividend payment date
Redrow PLCdividend payment date
Regional REIT Ltdex-dividend payment date
Schroder Oriental Income Fund Ltdex-dividend payment date
Scottish American Investment Co PLCex-dividend payment date
SCS Group PLCex-dividend payment date
Shell PLCex-dividend payment date
Supermarket Income REIT PLCdividend payment date
UK Commercial Property REIT Ltdex-dividend payment date
Unilever PLCex-dividend payment date
Wincanton PLCex-dividend payment date
  
Copyright 2023 Alliance News Ltd. All Rights Reserved.

Read more
8 Nov 2023 09:30

LONDON BROKER RATINGS: UBS downbeat on AJ Bell and Hargreaves Lansdown

(Alliance News) - The following London-listed shares received analyst recommendations Wednesday morning and Tuesday:

Read more
2 Nov 2023 10:14

LONDON BROKER RATINGS: Bank of America starts Unite Group with 'buy'

(Alliance News) - The following London-listed shares received analyst recommendations Thursday morning and Wednesday:

Read more
1 Nov 2023 16:52

LONDON MARKET CLOSE: Stocks prosper ahead of central bank rate calls

(Alliance News) - Stocks in London took their lead from a positive start on Wall Street to close higher as investors prepare for interest rate decisions in the UK and US.

Read more
1 Nov 2023 16:35

London close: Stocks rise ahead of US Fed policy decision

(Sharecast News) - London's stock market finished in positive territory on Wednesday, with investors keeping a keen eye on the upcoming policy announcement from the US Federal Reserve.

Read more
1 Nov 2023 08:51

TOP NEWS: GSK ups guidance as boosted by Shingrix and Arexvy

(Alliance News) - GSK PLC on Wednesday hailed the performance of the world's first approved respiratory syncytial virus vaccine Arexvy, as it reported a rise in profit and revenue.

Read more
1 Nov 2023 08:50

LONDON MARKET OPEN: FTSE 100 up, FTSE 250 down as Aston Martin tumbles

(Alliance News) - Stock prices in London opened mixed on Wednesday, ahead of key central bank decisions, as investors were cheered by some strong updates from large-cap listings.

Read more
1 Nov 2023 07:40

LONDON BRIEFING: GSK raises annual guidance following Arexvy launch

(Alliance News) - Stocks in London are called higher on Wednesday, with the main focal point for the day being the upcoming US interest rate decision.

Read more
1 Nov 2023 07:27

GSK hikes guidance after strong third quarter

(Sharecast News) - GSK announced a robust third quarter on Wednesday, prompting an upgrade to its full-year guidance.

Read more
30 Oct 2023 09:01

IN BRIEF: GSK says Jemperli meets endpoint in endometrial cancer trial

GSK PLC - Brentford, west London-based pharmaceutical maker - Jemperli, whose generic name is dostarlimab, meets endpoint of overall survival in phase III Ruby trial on adult patients with primary advanced or recurrent endometrial cancer. Jemperli, combined with standard-of-care chemotherapy, followed by dostarlimab, demonstrated a "statistically significant and clinically meaningful benefit" to the patients in the trial.

Read more
30 Oct 2023 07:06

GSK's Jemperli sees success in endometrial cancer trial

(Sharecast News) - GSK reported encouraging outcomes from part one of the 'RUBY' phase three trial evaluating the efficacy of 'Jemperli', or dostarlimab, with standard chemotherapy for treating adult patients with advanced or recurrent endometrial cancer on Monday.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.